Minutes of the CHMP Meeting 9-12 November 2020
Total Page:16
File Type:pdf, Size:1020Kb
05 January 2021 EMA/CHMP/708314/2020 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 09-12 November 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction 8 1.1. Welcome and declarations of interest of members, alternates and experts ............ 8 1.2. Adoption of agenda ................................................................................................ 8 1.3. Adoption of the minutes ......................................................................................... 8 2. Oral Explanations 9 2.1. Pre-authorisation procedure oral explanations ....................................................... 9 2.1.1. glucagon - EMEA/H/C/005391 ..................................................................................... 9 2.1.2. somapacitan - Orphan - EMEA/H/C/005030 .................................................................. 9 2.2. Re-examination procedure oral explanations ......................................................... 9 2.2.1. Elzonris - tagraxofusp - Orphan - EMEA/H/C/005031 ..................................................... 9 2.2.2. Gamifant - emapalumab - Orphan - EMEA/H/C/004386 ................................................ 10 2.3. Post-authorisation procedure oral explanations ................................................... 10 2.4. Referral procedure oral explanations ................................................................... 10 3. Initial applications 11 3.1. Initial applications; Opinions ................................................................................ 11 3.1.1. Onbevzi - bevacizumab - EMEA/H/C/005640 ............................................................... 11 3.1.2. Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386 ............................................. 11 3.1.3. Roclanda - netarsudil / latanoprost - EMEA/H/C/005107 ............................................... 12 3.1.4. Xofluza - baloxavir marboxil - EMEA/H/C/004974 ........................................................ 12 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ...................................................................... 13 3.2.1. estetrol / drospirenone - EMEA/H/C/005336................................................................ 13 3.2.2. trastuzumab deruxtecan - EMEA/H/C/005124 ............................................................. 13 3.2.3. estetrol / drospirenone - EMEA/H/C/005382................................................................ 13 3.2.4. glucagon - EMEA/H/C/005391 ................................................................................... 13 3.2.5. somapacitan - Orphan - EMEA/H/C/005030 ................................................................ 14 3.2.6. adalimumab - EMEA/H/C/005188 .............................................................................. 14 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ...................................................................... 15 3.3.1. abiraterone acetate - EMEA/H/C/005649 .................................................................... 15 3.3.2. lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - ATMP - EMEA/H/C/00473115 3.3.3. dabigatran etexilate - EMEA/H/C/005639 .................................................................... 15 3.3.4. risdiplam - Orphan - EMEA/H/C/005145 ..................................................................... 15 3.3.5. imatinib - EMEA/H/C/005595 .................................................................................... 16 3.4. Update on on-going initial applications for Centralised procedure ........................ 16 3.4.1. abiraterone acetate - EMEA/H/C/005408 .................................................................... 16 Committee for medicinal products for human use (CHMP) EMA/CHMP/708314/2020 Page 2/53 3.4.2. risperidone - EMEA/H/C/005406 ................................................................................ 16 3.4.3. satralizumab - Orphan - EMEA/H/C/004788 ................................................................ 17 3.4.4. bevacizumab - EMEA/H/C/005433 ............................................................................. 17 3.4.5. tirbanibulin mesilate - EMEA/H/C/005183 ................................................................... 17 3.4.6. tafasitamab - Orphan - EMEA/H/C/005436 .................................................................. 17 3.4.7. eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352 ................................... 18 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 ............................................................................................................. 18 3.5.1. Aplidin - plitidepsin - Orphan - EMEA/H/C/004354 ....................................................... 18 3.5.2. Elzonris - tagraxofusp - Orphan - EMEA/H/C/005031 ................................................... 18 3.5.3. Gamifant - emapalumab - Orphan - EMEA/H/C/004386 ................................................ 19 3.6. Initial applications in the decision-making phase ................................................. 19 3.7. Withdrawals of initial marketing authorisation application .................................. 20 3.7.1. Puldysa - idebenone - Orphan - EMEA/H/C/005123 ...................................................... 20 3.7.2. Roctavian - valoctocogene roxaparvovec - Orphan - ATMP - EMEA/H/C/004749 ............... 20 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 20 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion ................................................................................ 20 4.1.1. Nuceiva - botulinum toxin type A - EMEA/H/C/004587/X/0005 ...................................... 20 4.1.2. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G ...................................... 21 4.1.3. Tivicay - dolutegravir - EMEA/H/C/002753/X/0058/G ................................................... 21 4.1.4. Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0008/G .................................................................................... 22 4.1.5. Xarelto - rivaroxaban - EMEA/H/C/000944/X/0074/G ................................................... 23 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues ....................................... 23 4.2.1. Diacomit - stiripentol - EMEA/H/C/000664/X/0032 ....................................................... 23 4.2.2. Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781/X/0014/G ............................................................................................................................. 24 4.2.3. Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007 ....................................... 24 4.2.4. Sirturo - bedaquiline - Orphan - EMEA/H/C/002614/X/0036/G ...................................... 24 4.2.5. Temybric Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/005254/X/0004/G .................................................................................... 25 4.2.6. Tepadina - thiotepa - EMEA/H/C/001046/X/0036 ......................................................... 25 4.2.7. Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/X/0012/G ............................................................................................................................. 26 4.2.8. Tysabri - natalizumab - EMEA/H/C/000603/X/0116 ...................................................... 26 4.3. Extension of marketing authorisation according to Annex I